In the study by Klein et al. [20] within-patient variability was significantly lower with insulin detemir than with insulin glargine in patients with type 2 diabetes, both in terms of the overall 24-h glucose lowering effect (47 vs. 215% variation) and the maximal glucose lowering effect (40 vs. 147% variation). Here, INS is linked to type 2 diabetes mellitus.